HOME >> MEDICINE >> NEWS
Enbrel provides sustained clinical improvements for ankylosing spondylitis for up to 3 years

THOUSAND OAKS, Calif., November 13, 2006 -- Amgen (NASDAQ: AMGN), today announced that data from an ongoing open-label, multinational, phase 4 extension study showed that patients with ankylosing spondylitis (AS) who received treatment with Enbrel? (etanercept) experienced sustained improvement in signs and symptoms, spinal mobility and physical function over 148 to 160 weeks of therapy. These results are consistent with an ENBREL phase 3 clinical trial at 24 weeks. The 160-week results will be presented at the American College of Rheumatology (ACR) Scientific Meeting in Washington, D.C.

"These data demonstrate that ENBREL can provide substantial long-term improvement in AS symptoms such as total back pain and spinal mobility," said Joachim Sieper, M.D., professor of rheumatology, Charite University in Berlin, Germany. "Because AS is a chronic inflammatory disease that requires ongoing management, it is important to offer patients a treatment option that is effective, has an established safety profile, and can be used over the long-term."

Data presented at ACR showed that 59 patients who received open-label ENBREL treatment for up to 160 weeks experienced sustained clinical improvements. Overall, 78 percent of patients (n=46) continuing treatment with ENBREL achieved a 20 percent improvement in the Assessment on Ankylosing Spondylitis Response Criteria (ASAS 20) after 160 weeks of treatment. ASAS is a composite measure of improvement in AS symptoms that include total back pain, patient assessment of disease activity, inflammation and physical function. Thirty-one percent of patients (n= 18) achieved partial remission at week 160. Partial remission, as defined by ASAS, is a low disease activity level (score < 20 units out of 100 in each of the four ASAS criteria).

Additional ENBREL data presented at ACR from this phase 4 extension study show that improvement in spinal mobility was also sustained through 148 to 160 weeks of
'"/>

Contact: Sonia Fiorenza
805-447-1604
Porter Novelli
13-Nov-2006


Page: 1 2 3

Related medicine news :

1. Rheumatoid arthritis patients can benefit from Enbrel in combination with methotrexate
2. Sports concussion research using fMRI provides insight for safe return-to-play decisions
3. Fluorescence diffuse optical tomography provides high contrast, 3-D look at breast cancer
4. Daytrana provides significant effectiveness in both boys and girls with ADHD
5. New book provides unprecedented look at role of religion over a lifetime
6. New edition of medical reference book provides the latest in hematology
7. Lung cancer screening regimen provides opportunity for cure
8. MERLIN TIMI-36 study provides new safety and efficacy data for unique anti-anginal therapy
9. IceSAR campaign provides glimpse of future Sentinel-1 images over ice
10. Darunavir with FUZEON provides HIV patients a better chance to reach undetectable viral load
11. Optical technique provides improved virtual biopsies of internal surfaces

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/28/2017)... ... May 28, 2017 , ... ... proud to announce that Jorge Fernandez-Silva, M.D., has joined its new Melbourne pain ... specialty that concentrates on minimally invasive techniques to treat and manage many types ...
(Date:5/27/2017)... ... 2017 , ... A May 8 article on CBCNews reports that ... issues that are not responsive to antibiotics nevertheless obtain prescriptions for them. The article ... for the problem both in Canada and the United States. Dr. Michael Farzam of ...
(Date:5/27/2017)... ... May 27, 2017 , ... From May 21-23, hearing healthcare ... three-day event was held at the Marriott Syracuse Downtown Hotel in Syracuse, New York. ... and network of independent hearing healthcare providers to help them stay ahead in the ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... week to review more than eighty-nine grant submissions all vying for nearly $1,000,000 ... in the Parkinson’s field.     , The American Parkinson Disease Association (APDA) is focused ...
(Date:5/26/2017)... Plano, Texas (PRWEB) , ... May 26, 2017 , ... ... Cord Stimulation System, a powerfully versatile, patient-centric spinal cord stimulation system. The Nuvectra™ Algovita ... , “We are pleased to be the first in Arkansas to introduce the ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... May 9, 2017  Semler Scientific, Inc. (OTCQB: ... solutions to improve the clinical effectiveness and efficiency ... the first quarter ended March 31, 2017. ... our customers to identify when preventive care options ... events like heart attacks or strokes occur," said ...
(Date:5/8/2017)... , May 8, 2017  Diplomat Pharmacy, Inc. ... Communications, Inc. ("WRB"), a health care service center ... WRB specializes in relationship management programs for ... WRB will join ... commercialization support services for manufacturers, biotech firms, and other ...
(Date:5/6/2017)... CHICAGO , May 5, 2017  May is ... of one of the most important methods to prevent ... to the Centers for Disease Control and Prevention, undetected ... stroke. 1 Omron, the global leader in personal ... on the elimination of heart attack and stroke and ...
Breaking Medicine Technology:
Cached News: